{"id":7154,"date":"2025-04-28T11:13:39","date_gmt":"2025-04-28T09:13:39","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=7154"},"modified":"2025-04-28T21:10:29","modified_gmt":"2025-04-28T19:10:29","slug":"perioperative-tislelizumab-plus-neoadjuvant-chemotherapy-for-patients-with-resectable-non-small-cell-lung-cancer-rationale-315-an-interim-analysis-of-a-randomised-clinical-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/perioperative-tislelizumab-plus-neoadjuvant-chemotherapy-for-patients-with-resectable-non-small-cell-lung-cancer-rationale-315-an-interim-analysis-of-a-randomised-clinical-trial\/","title":{"rendered":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-7154","publication","type-publication","status-publish","hentry","disease_state-non-small-cell-lung-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/7154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7154"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}